A Compassionate Use (CU) Program of Odronextamab
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT05619367
- Status
- Available
Conditions
- B-Cell Non-Hodgkin Lymphoma (NHL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- High-Grade B-Cell Lymphoma (HGBCL)
- Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Odronextamab — DRUG
Study Details
Provide compassionate use of odronextamab
Key Dates
- Status verified
- Dec 2025
Central Contacts
- Requests for compassionate use must be initiated by a treating physician Physicians should contact844-734-6643
Related Studies
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesPHASE1 · Recruiting · Nurix Therapeutics, Inc. · Duarte, California
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaPHASE3 · Recruiting · Regeneron Pharmaceuticals · Los Angeles, California
- A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHPPHASE2 · Recruiting · Danielle Wallace · Rochester, New York
- CD45BE-HSPC + CART-45 CellsPHASE1 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania